SI2743348T1 - Novel anti-human ngf antibody - Google Patents
Novel anti-human ngf antibody Download PDFInfo
- Publication number
- SI2743348T1 SI2743348T1 SI201231222T SI201231222T SI2743348T1 SI 2743348 T1 SI2743348 T1 SI 2743348T1 SI 201231222 T SI201231222 T SI 201231222T SI 201231222 T SI201231222 T SI 201231222T SI 2743348 T1 SI2743348 T1 SI 2743348T1
- Authority
- SI
- Slovenia
- Prior art keywords
- fab
- fragment
- antibody
- human ngf
- polynucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011176209 | 2011-08-11 | ||
| JP2011269215 | 2011-12-08 | ||
| EP12821758.5A EP2743348B1 (en) | 2011-08-11 | 2012-08-10 | Novel anti-human ngf antibody |
| PCT/JP2012/070433 WO2013022083A1 (ja) | 2011-08-11 | 2012-08-10 | 新規抗ヒトｎｇｆ抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2743348T1 true SI2743348T1 (en) | 2018-04-30 |
Family
ID=47668585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201231222T SI2743348T1 (en) | 2011-08-11 | 2012-08-10 | Novel anti-human ngf antibody |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8986952B2 (enExample) |
| EP (1) | EP2743348B1 (enExample) |
| JP (1) | JP5376095B2 (enExample) |
| KR (1) | KR101999867B1 (enExample) |
| CN (1) | CN103748222B (enExample) |
| AR (1) | AR087506A1 (enExample) |
| AU (1) | AU2012293161B2 (enExample) |
| BR (1) | BR112014002576B1 (enExample) |
| CA (1) | CA2841181C (enExample) |
| CY (1) | CY1119914T1 (enExample) |
| DK (1) | DK2743348T3 (enExample) |
| EA (1) | EA024292B1 (enExample) |
| ES (1) | ES2663968T3 (enExample) |
| HR (1) | HRP20180155T1 (enExample) |
| HU (1) | HUE036079T2 (enExample) |
| IL (1) | IL230797A (enExample) |
| IN (1) | IN2014CN00614A (enExample) |
| LT (1) | LT2743348T (enExample) |
| ME (1) | ME02944B (enExample) |
| MX (1) | MX351273B (enExample) |
| NO (1) | NO2743348T3 (enExample) |
| PH (1) | PH12014500001A1 (enExample) |
| PL (1) | PL2743348T3 (enExample) |
| PT (1) | PT2743348T (enExample) |
| RS (1) | RS56876B1 (enExample) |
| SI (1) | SI2743348T1 (enExample) |
| SM (1) | SMT201800166T1 (enExample) |
| TW (1) | TWI554519B (enExample) |
| WO (1) | WO2013022083A1 (enExample) |
| ZA (1) | ZA201400741B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| NZ611076A (en) | 2010-12-01 | 2015-09-25 | Alderbio Holdings Llc | Anti-ngf compositions and use thereof |
| JP6135161B2 (ja) * | 2013-02-08 | 2017-05-31 | アステラス製薬株式会社 | 新規抗ヒトｎｇｆ抗体 |
| US9127055B2 (en) | 2013-02-08 | 2015-09-08 | Astellas Pharma Inc. | Method of treating pain with anti-human NGF antibody |
| US11260124B2 (en) * | 2015-05-22 | 2022-03-01 | Astellas Pharma Inc. | Anti-human NGF antibody Fab fragment and methods for treating postoperative pain related to NGF |
| EP3434283A4 (en) * | 2016-03-25 | 2019-11-13 | Astellas Pharma Inc. | MEDICAL COMPOSITION WITH A FAB 'FRAGMENT OF A HUMAN ANTI-NGF ANTIBODY AGAINST PEG |
| CN109929035B (zh) * | 2017-12-15 | 2022-06-28 | 安源医药科技（上海）有限公司 | 抗人ngf抗体及其制备方法和用途 |
| JPWO2019221097A1 (ja) | 2018-05-15 | 2021-05-27 | アステラス製薬株式会社 | 抗ヒトｎｇｆ抗体又はその抗原結合フラグメントを有効成分とする心房細動の抑制用医薬組成物 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US6114143A (en) | 1993-03-11 | 2000-09-05 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Anti-HIV monoclonal antibody |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP2340849A1 (en) | 2001-05-30 | 2011-07-06 | Genentech, Inc. | Anti-NGF antibodies for the treatment of various disorders |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| EP2270048B1 (en) | 2002-12-24 | 2015-11-11 | Rinat Neuroscience Corp. | Anti-NGF antibodies and methods using same |
| MEP31508A (hr) | 2003-07-15 | 2010-10-10 | Amgen Inc | Humana anti-ngf neutrališuća antitijela kao selektivni ihibitori ngf signalne kaskade |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| EP2298345A3 (en) | 2005-01-24 | 2012-03-21 | MedImmune Limited | Specific binding members for NGF |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| MY161564A (en) * | 2007-08-10 | 2017-04-28 | Regeneron Pharma | High affinity human antibodies to human nerve growth factor |
| RU2461551C2 (ru) | 2007-10-24 | 2012-09-20 | Астеллас Фарма Инк. | Азолкарбоксамидное соединение или его фармацевтически приемлемая соль |
| KR20120088550A (ko) | 2009-05-04 | 2012-08-08 | 애보트 리서치 비.브이. | 증진된 생체내 안정성을 갖는 신경 성장 인자(ｎｇｆ)에 대한 항체 |
-
2012
- 2012-08-10 JP JP2013525474A patent/JP5376095B2/ja not_active Expired - Fee Related
- 2012-08-10 RS RS20180173A patent/RS56876B1/sr unknown
- 2012-08-10 EA EA201490433A patent/EA024292B1/ru not_active IP Right Cessation
- 2012-08-10 MX MX2014001627A patent/MX351273B/es active IP Right Grant
- 2012-08-10 BR BR112014002576-2A patent/BR112014002576B1/pt not_active IP Right Cessation
- 2012-08-10 SM SM20180166T patent/SMT201800166T1/it unknown
- 2012-08-10 PH PH1/2014/500001A patent/PH12014500001A1/en unknown
- 2012-08-10 AU AU2012293161A patent/AU2012293161B2/en not_active Ceased
- 2012-08-10 KR KR1020147003155A patent/KR101999867B1/ko not_active Expired - Fee Related
- 2012-08-10 WO PCT/JP2012/070433 patent/WO2013022083A1/ja not_active Ceased
- 2012-08-10 LT LTEP12821758.5T patent/LT2743348T/lt unknown
- 2012-08-10 HR HRP20180155TT patent/HRP20180155T1/hr unknown
- 2012-08-10 PL PL12821758T patent/PL2743348T3/pl unknown
- 2012-08-10 PT PT128217585T patent/PT2743348T/pt unknown
- 2012-08-10 ES ES12821758.5T patent/ES2663968T3/es active Active
- 2012-08-10 CN CN201280039293.3A patent/CN103748222B/zh not_active Expired - Fee Related
- 2012-08-10 AR ARP120102927 patent/AR087506A1/es active IP Right Grant
- 2012-08-10 TW TW101128963A patent/TWI554519B/zh not_active IP Right Cessation
- 2012-08-10 CA CA2841181A patent/CA2841181C/en active Active
- 2012-08-10 ME MEP-2018-28A patent/ME02944B/me unknown
- 2012-08-10 HU HUE12821758A patent/HUE036079T2/hu unknown
- 2012-08-10 EP EP12821758.5A patent/EP2743348B1/en active Active
- 2012-08-10 NO NO12821758A patent/NO2743348T3/no unknown
- 2012-08-10 SI SI201231222T patent/SI2743348T1/en unknown
- 2012-08-10 US US13/879,267 patent/US8986952B2/en active Active
- 2012-08-10 IN IN614CHN2014 patent/IN2014CN00614A/en unknown
- 2012-08-10 DK DK12821758.5T patent/DK2743348T3/en active
-
2014
- 2014-01-30 ZA ZA2014/00741A patent/ZA201400741B/en unknown
- 2014-02-03 IL IL230797A patent/IL230797A/en active IP Right Grant
-
2015
- 2015-01-14 US US14/596,874 patent/US20150218265A1/en not_active Abandoned
-
2018
- 2018-02-14 CY CY20181100180T patent/CY1119914T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014500001A1 (en) | Novel anti-human ngf antibody | |
| NZ611468A (en) | Humanized antibodies to liv-1 and use of same to treat cancer | |
| CY1119445T1 (el) | Αντισωματα εναντι του ανθρωπινου gdf8 | |
| HRP20201505T1 (hr) | Široko neutralizirajuća anti-hiv protutijela | |
| PE20142242A1 (es) | Anticuerpos humanos anti-cd27, metodos, y usos | |
| BR112014002613A2 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método | |
| NZ706377A (en) | Il-6 antagonists and uses thereof | |
| EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
| EA035160B9 (ru) | Антитела к st2 и их применение | |
| MX347829B (es) | Molécula fv de unión a antígeno multivalente. | |
| BR112012021327B8 (pt) | anticorpo monoclonal anti-her2 humanizado, método de preparação e uso do mesmo. | |
| EA201491569A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
| MX338758B (es) | Anticuerpos monoclonales humanos, derivados de celulas b humanas, y que tienen actividad neutralizante contra el virus de la influenza a. | |
| EA201591113A1 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение | |
| WO2013144566A3 (en) | Animals expressing human lambda immunoglobulin light chain variable domain | |
| NZ714516A (en) | Human antibodies to clostridium difficile toxins | |
| MY172428A (en) | Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient | |
| RU2013135175A (ru) | Фармацевтическая композиция комплекса антитела против дигоксигенина и дигоксигенина, конъюгированного с пептидом | |
| AR098663A1 (es) | Anticuerpos multifuncionales que se unen a egfr y met | |
| JOP20190103A1 (ar) | شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري | |
| MY177098A (en) | Novel anti-human tslp receptor antibody | |
| MX2016008520A (es) | Anticuerpo bdca-2 antihumano novedoso. | |
| EA201400447A1 (ru) | АНТИТЕЛА К CD1d | |
| CN104245736A (zh) | 抗人死亡受体5胞外区的人源化单克隆抗体 | |
| MX2013011414A (es) | Novedoso anticuerpo anti-receptor de il-23 humano. |